TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28814393

Group type: EXPERIMENTAL
Intervention: FSMS-RUTF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSMS-RUTF
Number of subjects: 0

Group type: COMPARATOR
Intervention: PM-RUTF
Number of subjects: 0
Study: 25798601

Group type: EXPERIMENTAL
Intervention: 90% of maximal sprint velocity with supervision (90SUP, n = 10)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 100% intensity without supervision (100UNSUP, n = 13)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 90% of maximal sprint velocity without supervision (90UNSUP, n = 13)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Regular soccer training (Control group, CON, n = 9)
Number of subjects: 45
Study: 24197584

Group type: EXPERIMENTAL
Intervention: Levosimendan therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study: 20715906

Group type: EXPERIMENTAL
Intervention: Yoghurt and bread enriched with biologically active substances
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (Control Group II)
Number of subjects: 80
Study: 19187340

Group type: EXPERIMENTAL
Intervention: PGE(2) infusion (0.40 microg kg(‐1) min(‐1))
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 11
Study: 16731393

Group type: EXPERIMENTAL
Intervention: Anterior midline point stop (AMPS) device
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Full-arch stabilization splint
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 15588139

Group type: EXPERIMENTAL
Intervention: Breast cancer (CaB)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Colorectal cancer (CaC)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group (without oncological diseases)
Number of subjects: 183
Study: 11536222

Group type: EXPERIMENTAL
Intervention: Modified-release (MR) dosage forms of metformin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Immediate-release (IR) dosage forms of metformin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Modified-release (MR) formulations of metformin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Basic convolution level A model using in vitro dissolution as in vivo input
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Extended convolution approach modeling absorption using a Hill function
Number of subjects: 8
Study: 9340970

Group type: EXPERIMENTAL
Intervention: Platinum containing re‐induction chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormonal treatment (tamoxifen or GnRH analogues)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy with topoisomerase blocking agents, taxanes, or alkylating agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8485203

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (tretinoin) for AML M3
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Standard treatment for AML M4Eo
Number of subjects: 594

Group type: COMPARATOR
Intervention: Other FAB types combined
Number of subjects: 594
Study: 3691693

Group type: EXPERIMENTAL
Intervention: Foveally stabilized target on a dark field
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Foveally stabilized point target on a sinusoidally moving non‐stabilized background
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pseudo‐random background movement
Number of subjects: 6
Study: 29885390

Group type: EXPERIMENTAL
Intervention: Telemedicine support for GDM care
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 95
Study: 26417057

Group type: EXPERIMENTAL
Intervention: Growth differentiation factor-15 (GDF-15) levels
Number of subjects: 16876
Study: 24614012

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23528580

Group type: EXPERIMENTAL
Intervention: Mexidol (375 mg daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Antidepressants (fevarin 150 mg daily)
Number of subjects: 70
Study: 20434674

Group type: EXPERIMENTAL
Intervention: Electrosurgery
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard sharp debridement (Control)
Number of subjects: 59
Study: 18950383

Group type: EXPERIMENTAL
Intervention: 25 mg dose of amitriptyline
Number of subjects: 17
Study: 16192503

Group type: EXPERIMENTAL
Intervention: Cavitation Ultrasonic Surgical Aspirator (CUSA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clamp‐crushing method (CC group)
Number of subjects: 50
Study: 12452403

Group type: EXPERIMENTAL
Intervention: Hypnosis treatment (seven biweekly sessions and home audiotapes)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hypnosis treatment
Number of subjects: 42
Study: 10599010

Group type: EXPERIMENTAL
Intervention: Intensive counselling at the start of treatment and at each subsequent visit for ambulatory patients, or weekly for hospitalised patients.
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1019

Group type: EXPERIMENTAL
Intervention: Intensive counselling (intervention).
Number of subjects: 1019
Study: 7627507

Group type: EXPERIMENTAL
Intervention: Autotransfusion using Haemocell S‐350 device
Number of subjects: 17

Group type: COMPARATOR
Intervention: Bank blood control
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 0.6‐micron pore size filter
Number of subjects: 17
Study: 1773490

Group type: EXPERIMENTAL
Intervention: Turbidimetric assay
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: All assays (including turbidimetric, Kodak, Poli, and immunochemical)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Turbidimetric procedure from Boehringer, two enzymatic approaches from Kodak and Poli, and an immunochemical assay
Number of subjects: 46
Study: 7075566

Group type: EXPERIMENTAL
Intervention: Traditional cleansing enemas
Number of subjects: 93

Group type: COMPARATOR
Intervention: New simpler oral cleansing preparation
Number of subjects: 93
Study: 31962346

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment for primary headache (8-11 sessions, including vasoconstriction/vasodilation training for migraine and electromyography training for tension-type headache)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waiting control group (no treatment)
Number of subjects: 70
Study: 29985874

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (EES) at a dose of 50 mg . kg . day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 27684813

Group type: EXPERIMENTAL
Intervention: Tablet-based box trainer (TBT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard box trainer (SBT)
Number of subjects: 32
Study: 24909799

Group type: EXPERIMENTAL
Intervention: β-cryptoxanthin (0.75 mg/day) plus phytosterols (1.5 g/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: β-cryptoxanthin (0.75 mg/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: phytosterols (1.5 g/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: β-cryptoxanthin plus phytosterols
Number of subjects: 38
Study: 23043951

Group type: EXPERIMENTAL
Intervention: Prostaglandin F (PGF) 2 mL per fish in 2009/2010 season and 5 mL per fish in 2010/2011 season, in addition to carp pituitary extract (6 mg/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Carp pituitary extract (6 mg/kg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prostaglandin F (PGF)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prostaglandin F (PGF) and carp pituitary extract
Number of subjects: 45
Study: 20629111

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 88
Study: 19002089

Group type: EXPERIMENTAL
Intervention: 1 set of progressive resistance exercises
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2 sets of progressive resistance exercises
Number of subjects: 100
Study: 16463827

Group type: EXPERIMENTAL
Intervention: Intracranial pressure > 20 mmHg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intracranial pressure < 20 mmHg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Day 1 after SAH
Number of subjects: 36
Study: 12431041

Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate .025% ophthalmic solution
Number of subjects: 495

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495
Study: 10875870

Group type: EXPERIMENTAL
Intervention: Orientation of the first polar body at 6 o'clock
Number of subjects: 114

Group type: COMPARATOR
Intervention: Orientation of the first polar body at 12 o'clock
Number of subjects: 114
Study: 8575972

Group type: EXPERIMENTAL
Intervention: Vaccinated cows
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Calves from vaccinated cows
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Neonatally vaccinated calves
Number of subjects: 52

Group type: COMPARATOR
Intervention: Unvaccinated calves
Number of subjects: 52
Study: 1299590

Group type: COMPARATOR
Intervention: Thrombolytic treatment only (Group A)
Number of subjects: 98

Group type: COMPARATOR
Intervention: 3 g GL intravenously 15 min before thrombolysis (Group B)
Number of subjects: 98

Group type: COMPARATOR
Intervention: 6.25 mg CA orally 15 min before thrombolytic treatment (Group C)
Number of subjects: 98

Group type: COMPARATOR
Intervention: 3 g GL intravenously before thrombolysis and 6.25 mg CA orally (Group D)
Number of subjects: 98
Study: 6380554

Group type: EXPERIMENTAL
Intervention: 10 mg bd tamoxifen
Number of subjects: 263

Group type: COMPARATOR
Intervention: 20 mg bd tamoxifen
Number of subjects: 263
Study: 31188062

Group type: EXPERIMENTAL
Intervention: Negative emotions with low cognitive resources
Number of subjects: 174

Group type: COMPARATOR
Intervention: Neutral emotions with low cognitive resources
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Negative emotions with high cognitive resources
Number of subjects: 174

Group type: COMPARATOR
Intervention: Neutral emotions with high cognitive resources
Number of subjects: 174
Study: 29901816

Group type: EXPERIMENTAL
Intervention: Modified Atkins diet for 12 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Habitual diet (control group)
Number of subjects: 75
Study: 27156934

Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg subcutaneously weekly
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 87
Study: 1330565

Group type: EXPERIMENTAL
Intervention: Azithromycin (single-dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Doxycycline (seven-day course)
Number of subjects: 60
Study: 22800352

Group type: EXPERIMENTAL
Intervention: Anti-acid therapy and conventional pharyngo-laryngitis therapy in LPR group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Anti-acid therapy and conventional pharyngo-laryngitis therapy in control group
Number of subjects: 34
Study: 20394491

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% combined with fluticasone
Number of subjects: 376

Group type: COMPARATOR
Intervention: Fluticasone alone
Number of subjects: 376
Study: 18759257

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg (group 2)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo followed by infliximab 5 mg/kg (group 1)
Number of subjects: 279
Study: 15897310

Group type: EXPERIMENTAL
Intervention: Physiotherapy (exercise, massage, taping, and mobilisation)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (sham ultrasound and non-therapeutic gel)
Number of subjects: 140
Study: 12689932

Group type: EXPERIMENTAL
Intervention: Cord Blood (CB) transplant
Number of subjects: 24

Group type: COMPARATOR
Intervention: Adult Bone Marrow (BM) transplant
Number of subjects: 24
Study: 10584627

Group type: EXPERIMENTAL
Intervention: Uterine curettage under general anesthesia
Number of subjects: 55

Group type: COMPARATOR
Intervention: No further intervention (no curettage)
Number of subjects: 55
Study: 8592224

Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate 6 mg/kg per day
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Tirilazad mesylate 0.6 mg/kg per day
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Tirilazad mesylate 2 mg/kg per day
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 1023
Study: 1868479

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment alone for reflux grade III or less
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Surgery plus antibiotic treatment for reflux grade IV
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Reimplantation for reflux grade V
Number of subjects: 96

Group type: COMPARATOR
Intervention: Antibiotic treatment alone for reflux grade IV (control group)
Number of subjects: 96
Study: 6202972

Group type: EXPERIMENTAL
Intervention: Aspirin, 300 mg three times a day for 7 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 30614823

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading, followed by 90 mg twice daily
Number of subjects: 298
Study: 29336389

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study: 27412058

Group type: EXPERIMENTAL
Intervention: Bicuspid aortic valve patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (normal trileaflet aortic valve)
Number of subjects: 80
Study: 24314872

Group type: EXPERIMENTAL
Intervention: Acetabular Tridimensional Memory Fixation System (ATMFS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional screws and buttress plates (Plates group)
Number of subjects: 50
Study: 22515969

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (n = 552)
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Usual care (n = 541)
Number of subjects: 1093
Study: 20494923

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 6676

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6676
Study: 17763834

Group type: EXPERIMENTAL
Intervention: Prophylactic anticonvulsants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seizure prophylaxis with antiepileptic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Literature on prophylactic anticonvulsants
Number of subjects: 0
Study: 17414940

Group type: EXPERIMENTAL
Intervention: NT 201 (2, 4, 16, or 32 units)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Botox (BTXCo)
Number of subjects: 32
Study: 15815753

Group type: EXPERIMENTAL
Intervention: Percutaneous thrombectomy with the RESCUE system followed by stent implantation
Number of subjects: 72

Group type: COMPARATOR
Intervention: PCI with stent implantation alone
Number of subjects: 72
Study: 11232739

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care programme
Number of subjects: 1290

Group type: COMPARATOR
Intervention: Control group (no pharmaceutical care)
Number of subjects: 1290
Study: 9288859

Group type: EXPERIMENTAL
Intervention: 5‐ASA (4 g/day Pentasa)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 8321504

Group type: EXPERIMENTAL
Intervention: Eyes of black patients
Number of subjects: 271
Study: 3471376

Group type: EXPERIMENTAL
Intervention: Weekly 0.2% neutral NaF rinse
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control group (no fluoride rinse)
Number of subjects: 501
Study: 30954486

Group type: EXPERIMENTAL
Intervention: Uric acid (UA) treatment (16 mg/kg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Uric acid (UA) treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Vehicle (Locke's buffer)
Number of subjects: 2
Study: 28174212

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 783

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 783
Study: 25770870

Group type: EXPERIMENTAL
Intervention: Adaptation of the Helpful Responses Questionnaire (HRQ)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Multiple-choice CM knowledge test
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Recorded standardized patient encounter scored for CM skillfulness
Number of subjects: 19
Study: 24955290

Group type: EXPERIMENTAL
Intervention: 3-month multi-component intervention
Number of subjects: 136
Study: 21371292

Group type: EXPERIMENTAL
Intervention: Perioperative continuation of ASA
Number of subjects: 52

Group type: COMPARATOR
Intervention: Discontinuation of ASA (stopping ASA five days prior to surgery and starting on postoperative day 5)
Number of subjects: 52
Study: 20168107

Group type: EXPERIMENTAL
Intervention: One biopsy
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Two or more biopsies
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Zero biopsies
Number of subjects: 988
Study: 16775818

Group type: EXPERIMENTAL
Intervention: Quilting procedures
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no quilting)
Number of subjects: 108
Study: 15261228

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 12
Study: 11583189

Group type: EXPERIMENTAL
Intervention: Epirubicin plus cyclophosphamide (HEC)
Number of subjects: 481
Study: 9855147

Group type: EXPERIMENTAL
Intervention: Excimer laser photorefractive keratectomy
Number of subjects: 34
Study: 7863827

Group type: EXPERIMENTAL
Intervention: Age-related decline in speed of sound (SOS)
Number of subjects: 1405

Group type: EXPERIMENTAL
Intervention: Age-related decline in broadband ultrasound attenuation (BUA)
Number of subjects: 1405

Group type: EXPERIMENTAL
Intervention: Current corticosteroid use
Number of subjects: 1405

Group type: EXPERIMENTAL
Intervention: Severe disability
Number of subjects: 1405

Group type: EXPERIMENTAL
Intervention: Pack-years of smoking
Number of subjects: 1405

Group type: EXPERIMENTAL
Intervention: Ultrasound measurements (SOS and BUA) compared to bone mineral density (BMD)
Number of subjects: 1405
Study: 2574050

Group type: EXPERIMENTAL
Intervention: Sufotidine 600 mg once daily
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sufotidine 600 mg twice daily
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30584179

Group type: EXPERIMENTAL
Intervention: ASIR combined with 640-slice CT wide-detector volume scan
Number of subjects: 58

Group type: COMPARATOR
Intervention: ASIR combined with conventional spiral scan
Number of subjects: 58
Study: 27464913

Group type: EXPERIMENTAL
Intervention: Karydakis' flap procedure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Limberg's flap procedure
Number of subjects: 50
Study: 25985442

Group type: EXPERIMENTAL
Intervention: Anodal stimulation of the left DLPFC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cathodal stimulation of the left DLPFC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation of the left DLPFC
Number of subjects: 0
Study: 23793032

Group type: EXPERIMENTAL
Intervention: Email-based encouragements to walk the stairs for 10 minutes a day
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group receiving weekly reminders to continue their usual physical activities
Number of subjects: 160
Study: 21782470

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unguided injection
Number of subjects: 30
Study: 19533164

Group type: EXPERIMENTAL
Intervention: Upper limb resistance training (RT) at 80% of one repetition maximum, twice each week for 10 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lower limb resistance training (RT) at 80% of one repetition maximum, twice each week for 10 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 30
Study: 16709552

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-15 mg/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Risperidone (1-6 mg/d)
Number of subjects: 46
Study: 15329581

Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.1 microg x kg(‐1) x min(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11703440

Group type: EXPERIMENTAL
Intervention: Perindopril (PE)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (PO)
Number of subjects: 22
Study: 9407756

Group type: EXPERIMENTAL
Intervention: Diclofenac dispersible 50 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Naproxen granular 500 mg
Number of subjects: 48
Study: 8505452

Group type: EXPERIMENTAL
Intervention: Carbamide peroxide gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study: 3429683

Group type: EXPERIMENTAL
Intervention: Prazosin (twice daily for eight weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prazosin (once daily for eight weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Automated whole-day ambulatory blood pressure monitoring
Number of subjects: 12
Study: 30839494

Group type: EXPERIMENTAL
Intervention: Topical interferon α2b 1 MU/mL
Number of subjects: 50

Group type: COMPARATOR
Intervention: Artificial tear eye drop
Number of subjects: 50
Study: 27867204

Group type: EXPERIMENTAL
Intervention: 10TT
Number of subjects: 537

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 537
Study: 24762404

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification of Interpretations (CBM-I)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Test-retest control group
Number of subjects: 34
Study: 23264335

Group type: EXPERIMENTAL
Intervention: Multimodal therapy (MM)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 31
Study: 21622980

Group type: EXPERIMENTAL
Intervention: Relaxin given intravenously for 48 hours
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 19085546

Group type: EXPERIMENTAL
Intervention: Closed vault technique (group A)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Open vault technique (group B)
Number of subjects: 53
Study: 16880100

Group type: EXPERIMENTAL
Intervention: PB127 (0.175 mg/kg diluted in 5% dextrose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dipyridamole (0.56 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5% dextrose
Number of subjects: 20
Study: 12628263

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape
Number of subjects: 344

Group type: COMPARATOR
Intervention: Colposuspension
Number of subjects: 344
Study: 10848655

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d., clarithromycin 250 mg b.d., tinidazole 500 mg b.d. for 7 days (OCT)
Number of subjects: 2329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2329

Group type: EXPERIMENTAL
Intervention: OCT
Number of subjects: 2329